THERAPY DOSSIER · th-946307844963

GYY4137 (morpholin-4-ium-methoxyphenyl-morpholino-phosphinodithioate), a slow-releasing hydrogen sulfide donor

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28986598 ↗2017Reported benefit

Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo.

RatIschaemia-reperfusionOther / unspecifiedSprague-DawleyFemaleIntravitreal injection

Model: Ocular hypertension induced by episcleral vein cauterisation for 7 weeks; acute retinal ischaemic injury and optic nerve crush in vivo; retinal explants exposed to elevated hydrostatic pressure or hydrogen peroxide in vitro

Intraocular pressure elevation caused significant retinal ganglion cell loss and a threefold upregulation of the hydrogen sulfide producing enzyme 3-mercaptosulfurtransferase. GYY4137 protected retinal ganglion cells in a concentration-dependent manner in vitro and preserved cells after acute ischa…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…